$5.63
3.87% day before yesterday
Nasdaq, Sep 06, 10:00 pm CET
ISIN
US9186401033
Symbol
VCNX
Sector
Industry

Vaccinex, Inc. Stock price

$5.63
+0.69 13.96% 1M
-2.33 29.27% 6M
-3.68 39.51% YTD
-42.67 88.34% 1Y
-498.37 98.88% 3Y
-1,248.28 99.55% 5Y
-2,384.17 99.76% 10Y
Nasdaq, Closing price Fri, Sep 06 2024
+0.21 3.87%
ISIN
US9186401033
Symbol
VCNX
Sector
Industry

Key metrics

Market capitalization $9.73m
Enterprise Value $11.00m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 30.56
P/S ratio (TTM) P/S ratio 27.03
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth -56.85%
Revenue (TTM) Revenue $360.00k
EBIT (operating result TTM) EBIT $-21.62m
Free Cash Flow (TTM) Free Cash Flow $-15.77m
Cash position $230.00k
EPS (TTM) EPS $-25.01
Short interest 9.58%
Show more

Is Vaccinex, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Vaccinex, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Vaccinex, Inc. forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Vaccinex, Inc. forecast:

Buy
100%

Financial data from Vaccinex, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
0.36 0.36
57% 57%
100%
- Direct Costs 0.11 0.11
35% 35%
31%
0.25 0.25
62% 62%
69%
- Selling and Administrative Expenses 6.91 6.91
5% 5%
1,919%
- Research and Development Expense 15 15
6% 6%
4,125%
-22 -22
1% 1%
-5,975%
- Depreciation and Amortization 0.11 0.11
35% 35%
31%
EBIT (Operating Income) EBIT -22 -22
2% 2%
-6,005%
Net Profit -18 -18
19% 19%
-4,933%

In millions USD.

Don't miss a Thing! We will send you all news about Vaccinex, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vaccinex, Inc. Stock News

Neutral
GlobeNewsWire
24 days ago
ROCHESTER, N.Y., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Vaccinex (Nasdaq: VCNX) today provided an update on new clinical findings from its SIGNAL-AD Phase 1b/2 trial of pepinemab antibody in Alzheimer's disease.
Positive
Invezz
about one month ago
Vaccinex Inc (NASDAQ: VCNX) tanked an alarming 40% on Wednesday despite it reporting positive early-stage results for its Alzheimer's treatment.  The biotechnology company said its SIGNAL-AD trial established its pepinemab antibody as well-tolerated by patients of AD.
Neutral
GlobeNewsWire
3 months ago
Company expects to lock database in June andremains on track to report key outcomes later in July. Pepinemab targets astrocyte reactivity and neuroinflammation,believed to be key drivers of neurodegeneration.
More Vaccinex, Inc. News

Company Profile

Vaccinex, Inc. is a clinical-stage biotechnology company, which engages in the development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The firm focuses in the development of pepinemab for the treatment of non-small cell lung cancer, or NSCLC, osteosarcoma, melanoma and Huntington's disease. Its products pipeline includes SEMA4D antibody platform and ActivMAb antibody discovery platform. The company was founded by Maurice Zauderer and Deepak Sahasrabudhe in 1997 and is headquartered in Rochester, NY.

Head office United States
CEO Maurice Zauderer
Employees 40
Founded 1997
Website www.vaccinex.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today